Pharma Deals Review, Vol 2004, No 44 (2004)

Font Size:  Small  Medium  Large

Shire’s Exit Strategy from Japan Provides Bayer with Exclusive Product Rights

Business Review Editor

Abstract


Shire Pharmaceuticals has sold Bayer the exclusive rights to develop, market and sell FOSRENOL® in Japan in a deal worth up to US$70 M. FOSRENOL is indicated for treating hyperphosphatemia associated with End Stage Renal Disease.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.